OrthoPediatrics Q1 2024 Adj EPS $(0.30) Beats $(0.40) Estimate, Sales $44.685M Beat $41.775M Estimate
Portfolio Pulse from Benzinga Newsdesk
OrthoPediatrics (NASDAQ:KIDS) reported Q1 2024 adjusted EPS of $(0.30), surpassing the $(0.40) estimate, with sales of $44.685M exceeding the $41.775M forecast. This represents a 3.45% decrease in losses per share compared to last year, and a 41.46% increase in sales from the same period.
May 06, 2024 | 8:29 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
OrthoPediatrics reported a Q1 2024 adjusted EPS of $(0.30), beating estimates, with sales of $44.685M also surpassing expectations.
OrthoPediatrics' better-than-expected Q1 2024 earnings and sales growth significantly exceed analyst estimates, indicating strong operational performance and market demand for their products. This positive earnings surprise and substantial year-over-year sales increase are likely to instill investor confidence and could lead to a short-term uptick in the stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100